Shopping Cart
- Remove All
Your shopping cart is currently empty
Giredestrant (GDC-9545) potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity. Giredestrant, a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $113 | In Stock | |
| 5 mg | $236 | In Stock | |
| 10 mg | $372 | In Stock | |
| 25 mg | $715 | In Stock | |
| 50 mg | $1,130 | In Stock | |
| 100 mg | $1,790 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $273 | In Stock |
| Description | Giredestrant (GDC-9545) potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity. Giredestrant, a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. |
| In vitro | The highly potent in vivo efficacy of Giredestrant likely arises due to the particular combination of high binding potency, full suppression of ER signaling, and an improved DMPK profile.Giredestrant (GDC-9545) is a novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes. |
| Synonyms | GDC-9545 |
| Molecular Weight | 522.55 |
| Formula | C27H31F5N4O |
| Cas No. | 1953133-47-5 |
| Smiles | C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(F)(F)CO)c1c(F)cc(NC2CN(CCCF)C2)cc1F |
| Relative Density. | 1.333 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (191.37 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (7.65 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.